Showing results (121-130 of 158) with videos related to

Sort By:
Pageof 16
Nature Communications|March 29, 2025
Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunctionKuo Du, David S Umbaugh, Liuyang Wang, et al.
Contemporary Clinical Trials|March 3, 2021
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosisManal F Abdelmalek, Edgar D Charles, Arun J Sanyal, et al.
Hepatology (Baltimore, Md.)|October 24, 2017
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory scienceMohammad Shadab Siddiqui, Stephen A Harrison, Manal F Abdelmalek, et al.
Journal of Hepatology|August 26, 2018
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment optionsZobair Younossi, Maria Stepanova, Arun J Sanyal, et al.
Hepatology (Baltimore, Md.)|August 6, 2013
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver diseaseCynthia A Moylan, Herbert Pang, Andrew Dellinger, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)Danielle Brandman, Marie Boyle, Stuart McPherson, et al.
Journal of Hepatology|December 25, 2019
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertensionGuadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2023
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b StudyRohit Loomba, Arun J Sanyal, Atsushi Nakajima, et al.
Gut|March 20, 2012
NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver diseaseWing-Kin Syn, Kolade M Agboola, Marzena Swiderska, et al.
Lancet (London, England)|December 4, 2014
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, et al.
Pageof 16